aluminum
Aluminum is an element with an atomic number of 13. On the periodic table of elements its symbol is Al. It belongs to a group of metals including lead and tin. Aluminum has been used for a long time. During Ancient Egypt, aluminum oxides were used in their glazes and pottery. The Romans also used this metallic element. During the 1800s, advances in research made it possible to produce pure aluminum. Aluminium is used in a huge variety of products including cans, foils, kitchen utensils, window frames, beer kegs and aeroplane parts. This is because of its particular properties. It has low density, is non-toxic, has a high thermal conductivity, has excellent corrosion resistance and can be easily cast, machined and formed. It is also non-magnetic and non-sparking. It is the second most malleable metal and the sixth most ductile. It is often used as an alloy because aluminium itself is not particularly strong. Alloys with copper, manganese, magnesium and silicon are lightweight but strong. They are very important in the construction of aeroplanes and other forms of transport. Aluminium is a good electrical conductor and is often used in electrical transmission lines. It is cheaper than copper and weight for weight is almost twice as good a conductor. When evaporated in a vacuum, aluminium forms a highly reflective coating for both light and heat. It does not deteriorate, like a silver coating would. These aluminium coatings have many uses, including telescope mirrors, decorative paper, packages and toys. Aluminium has no known biological role. Aluminium can accumulate in the body, and a link with Alzheimer’s disease has been suggested but not proven. Aluminum-containing raw materials are used safely and extensively in cosmetics, pharmaceuticals and over-the-counter (OTC) drug products. In cosmetics, they function as pigments and thickening agents. Aluminum compounds also function as active ingredients in OTC drugs such as antacids and antiperspirants. Aluminum-containing ingredients have several uses in cosmetics and personal care products. Aluminum salts are used as antiperspirants to control sweat. Antiperspirant ingredients are regulated as over-the-counter (OTC) drugs by the U.S. Food and Drug Administration (FDA). A manufacturer can only use the aluminum active ingredients that have been approved as safe and effective by the FDA as listed in the OTC antiperspirant monograph. These products can only be used according to the guidelines established in this monograph. Aluminum may also be present in cosmetic colors. Aluminum powder is FDA approved and may be safely used in coloring externally applied cosmetics, including cosmetics intended for use in the area of the eye, [21 CFR §73.2645 Aluminum powder.]. In addition, aluminum is a common component in other cosmetic colors where it may be used as a substrate upon which another color is precipitated. Because the resulting color is not water-soluble, this can prevent ‘bleeding’, for example with lipstick. There are other uses of aluminum-containing ingredients in cosmetics, such as use as thickening agents. Under federal law, the safety of all ingredients must be substantiated by the manufacturer of the product before it is placed on the market. Aluminum compounds (alum) are the most widely used adjuvants in veterinary and human vaccines. Alum facilitates effectiveand long-lasting protective immunity in hosts, mainly by inducing antibody responses. Alum was found toinduce endogenous CD4+T cells and antibody production as well as to induce priming of CD8+T cells. These effects are shown to beindependent of the inflammasome. Novel findings of unexpected beneficial effects of decreased HBV (Hepatitis B virus) viral load and HBeAg seroconversion in chronically infected patients, as well as significant tumor suppression in experimental mice following multiple alum-only injections were examined, revealing alum's potential clinical applications beyond its use as a simple tool in antigen preparation. — NCATS
Clinical trial activity
39 trials · 54 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 1993 (NCT00697970)
Timeline
Indications
Approved for
Studied for
- Basal Cell Carcinoma · Phase 2
- Candidiasis · Phase 1
- Chlamydia trachomatis · Phase 1
- Condylomata Acuminata · Phase 1
- Dengue · Phase 1
- Dermatitis, Contact · Phase 2
- Dysentery, Bacillary · Phase 1
- Dyspepsia · Phase 4
- Enterovirus Infections · Phase 2
- Gastroesophageal Reflux · Phase 4
- Healthy Volunteers · Phase 2/Phase 3
- Hepatitis B · Phase 3
- Herpes Labialis · Phase 1/Phase 2
- HIV · Phase 1
- HIV Infections · Phase 1
- Hypersensitivity · Phase 1
- Influenza, Human · Phase 1
- Keratosis, Actinic · Phase 1
- Lyme Neuroborreliosis · Phase 1
- Melanoma · Phase 2
- Meningococcal Vaccines · Phase 1
- Pneumococcal Vaccines · Phase 1
- Pneumonia · Phase 1/Phase 2
- Pneumonia, Pneumococcal · Phase 1/Phase 2
- Poliomyelitis · Phase 2
- Pregnancy Complications · Phase 4
- Respiratory Syncytial Viruses · Phase 1
- Respiratory Syncytial Virus Infections · Phase 2
- Staphylococcal Infections · Phase 1
- Stomatitis, Aphthous · Phase 2
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
SMILES
O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].[Al+3].[Al+3]- Mol. weight
- 342.15 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPotassium alum ↗
- ChEMBLCHEMBL3833402 ↗
- NCATSCPD4NFA903 ↗
- ChEMBLCHEMBL3990987 ↗
- WikipediaAluminium ↗
- ChEMBLCHEMBL2105894 ↗
- ChEMBLCHEMBL3989545 ↗
- ChEMBLCHEMBL3833332 ↗
Also known as
- 13al
- 13al
- al
- al
- alum
- alum
- alum
- alum
- alum
- alum
- aluminio
- aluminio
- aluminium
- aluminium
- aluminium
- aluminium atom
- aluminium atom
- aluminium potassium sulfate
- aluminium potassium sulfate
- aluminium sulfate
- aluminium sulfate
- aluminium sulfate
- aluminium sulfate anhydrous
- aluminium sulfate anhydrous
- aluminum
- aluminum
- aluminum
- aluminum
- aluminum
- aluminum hydrogen sulfate
- aluminum potassium sulfate
- aluminum potassium sulfate
- aluminum potassium sulfate anhydrous
- aluminum potassium sulfate anhydrous
- aluminum salt
- aluminum salts
- aluminum sulfate
- aluminum sulfate
- aluminum sulfate
- aluminum sulfate
- aluminum sulphate anhydrous
- aluminum sulphate anhydrous
- alumninum
- alum potassium
- dialuminum sulfate
- dialuminum sulfate
- dialuminum trisulfate
- dialuminum trisulfate
- potash alum
- potash alum
- potash, sulfurated
- potash, sulfurated
- potassium alum
- potassium alum
- potassium alum
- potassium alum
- potassium alum
- potassium aluminium sulfate
- potassium aluminium sulfate
- potassium aluminum sulfate
- stingose
- stingose
- sulfurated potash
- sulfurated potash
- sulfurated potash
- zn sulfide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06905275 | Phase 1 | Jul 7, 2025 | Department of Health and Human Services, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT06666179 | Phase 1 | Mar 15, 2025 | Clover Biopharmaceuticals |
| NCT06241183 | Phase 4 | Nov 9, 2023 | Stony Brook University |
| NCT05903339 | Phase 1 | Aug 29, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05781542 | Phase 1 | Apr 10, 2023 | Access to Advanced Health Institute (AAHI), Department of Health and Human Services, HIV Vaccine Trials Network, Inovio Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), The Wistar Institute |
| NCT03010228 | Phase 1 | Jan 1, 2017 | Valneva |
| NCT02543892 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | PATH, University of London |
| NCT02810340 | Phase 1 | Aug 1, 2016 | PATH, University of Maryland |
| NCT02787109 | Phase 1 | Jul 1, 2016 | Statens Serum Institut, University of London |
| NCT02797236 | Phase 1 | Jun 1, 2016 | Institut Pasteur |
| NCT02470117 | Phase 4 | Jun 1, 2015 | Chulalongkorn University |
| NCT02472548 | Phase 1 | May 1, 2015 | Dalhousie University, ImmunoVaccine Technologies, Inc. |
| NCT02405520 | Phase 1 | Mar 1, 2015 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Government of China, University of Michigan, Xiamen University |
| NCT02347423 | Phase 2 | Feb 1, 2015 | Bill and Melinda Gates Foundation, IQVIA, Larix A/S, Statens Serum Institut |
| NCT02097472 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2014 | Kenya Medical Research Institute, PATH |
| NCT02097329 | Phase 1 | Apr 1, 2014 | Pfizer |
| NCT02028208 | Phase 2 | Nov 1, 2013 | Allerderm, Lund University |
| NCT01960686 | Phase 2 | Oct 1, 2013 | Novavax |
| NCT01734408 | Phase 2 | Nov 1, 2012 | Bejing Vigoo Biological Co., LTD, Government of China |
| NCT01702857 | Phase 1 | Nov 1, 2012 | GlaxoSmithKline, United States Army, University of Puerto Rico |
Organizations
Research & Development (54)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 4 | 3 | 1993 |
| Institut Pasteur | Academic/Hospital | 4 | 1 | 3 | 2007 |
| PATH | Academic/Hospital | 4 | 4 | 2 | 2012 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 1 | 2023 |
| University of London | Academic/Hospital | 3 | 1 | 3 | 2009 |
| Department of Health and Human Services | Government | 2 | 0 | 1 | 2023 |
| Government of China | Government | 2 | 1 | 2 | 2012 |
| Isfahan University | Academic/Hospital | 2 | 2 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 1998 |
| Razi Vaccine and Serum Research Institute | Academic/Hospital | 2 | 0 | 1 | 2007 |
| Statens Serum Institut | Academic/Hospital | 2 | 2 | 2 | 2015 |
| United States Army | Government | 2 | 2 | 1 | 2012 |
| Access to Advanced Health Institute (AAHI) | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Allerderm | For profit | 1 | 1 | 1 | 2013 |
| Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | For profit | 1 | 0 | 1 | 2015 |
| Bejing Vigoo Biological Co., LTD | For profit | 1 | 0 | 1 | 2012 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Chulalongkorn University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Clover Biopharmaceuticals | For profit | 1 | 1 | 1 | 2025 |
| Crucell | For profit | 1 | 0 | 1 | 2007 |